8-K Announcements
6Material company update
May 15, 2026·SEC
Material company update
May 11, 2026·SEC
Material company update
Apr 24, 2026·SEC
Sana Biotechnology, Inc.(SANA)Earnings, Financials & Key Ratios
SANA•NASDAQ
Price updated Jun 19, 2026
AboutSana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.Show more
- Revenue$0
- EBITDA-$178M+30.2%
- Net Income-$244M+8.5%
- EPS (Diluted)-0.96+17.2%
- ROE-118.7%-19.7%
SANA Key Insights
Sana Biotechnology, Inc. (SANA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when SANA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SANA Price & Volume
Sana Biotechnology, Inc. (SANA) stock price & volume — 10-year historical chart
Loading chart...
SANA Growth Metrics
Sana Biotechnology, Inc. (SANA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-15.96%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-4.55%
Return on Capital
10 Years-43.34%
5 Years-45.22%
3 Years-51.17%
Last Year-48.12%
SANA Recent Earnings
Sana Biotechnology, Inc. (SANA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.14+6.7%
$0.15
Rev
—
—
Q2 2026
Mar 3, 2026Metric
Actual
Est
EPS
$0.16-23.1%
$0.13
Rev
—
—
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.15+16.7%
$0.18
Rev
—
—
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.16+20.0%
$0.20
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.14vs $0.15+6.7% | — |
| Q2 2026 | Mar 3, 2026 | $0.16vs $0.13-23.1% | — |
| Q4 2025 | Nov 6, 2025 | $0.15vs $0.18+16.7% | — |
| Q3 2025 | Aug 11, 2025 | $0.16vs $0.20+20.0% | — |
Based on last 12 quarters of dataView full earnings history →
SANA Peer Comparison
Sana Biotechnology, Inc. (SANA) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 ALNY | 37.1B | 278.09 | 119.35 | 65.19% | 13.46% | 98.29% | 1.62 | |
 IONS | 12.25B | 74.12 | -31.14 | 33.87% | -30.87% | -58.57% | 5.35 | |
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 |
Compare SANA vs Peers
Sana Biotechnology, Inc. (SANA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SANA Income Statement
Sana Biotechnology, Inc. (SANA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 1K | 3.92M | 10.17M | 0 | 0 | 0 | 0 | 12.75M | 2.39M |
COGS % of Revenue | - | - | - | - | - | - | - | - | - |
Gross Profit | -1K▲ 0% | -3.92M▼ 392000.0% | -10.17M▼ 159.4% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -12.75M▲ 0% | -2.39M▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | -392000% | -159.4% | 100% | - | - | - | - | - |
Operating Expenses | 8.22M | 141.15M | 150.95M | 356.91M | 272.56M | 293.14M | 272.72M | 178.21M | 235.17M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 4.21M | 21.78M | 28.27M | 50.41M | 71.56M | 73.3M | 64.04M | 44.3M | 44.27M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
Research & Development | 4.01M | 119.38M | 122.68M | 306.5M | 201M | 219.84M | 208.68M | 131.98M | 146.28M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.93M | 1000K |
Operating Income | -8.22M▲ 0% | -141.15M▼ 1617.0% | -161.12M▼ 14.1% | -356.91M▼ 121.5% | -272.56M▲ 23.6% | -293.14M▼ 7.5% | -272.72M▲ 7.0% | -190.96M▲ 30.0% | -237.56M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | - | -1616.97% | -14.15% | -121.51% | 23.63% | -7.55% | 6.97% | 29.98% | - |
EBITDA | -8.22M | -137.23M | -150.95M | -345.84M | -256.94M | -268.58M | -255.33M | -178.21M | -226.07M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | - | -1569.48% | -10% | -129.11% | 25.71% | -4.53% | 4.93% | 30.21% | -15.73% |
D&A (Non-Cash Add-back) | 1K | 3.92M | 10.17M | 11.07M | 15.63M | 24.56M | 17.39M | 12.75M | 11.49M |
EBIT | -13.25M | -142.82M | -297.2M | -356.91M | -272.56M | -293.14M | -272.72M | -190.96M | -191.58M |
Net Interest Income | 0 | 2.86M | 747K | 676K | 3.76M | 9.94M | 10.47M | 3.85M | 962K |
Interest Income | 0 | 2.86M | 747K | 676K | 3.76M | 9.94M | 10.47M | 3.85M | 962K |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -5.03M | 2.83M | -136.08M | 981K | 3.09M | 9.89M | 5.96M | -53.21M | -4.43M |
Pretax Income | -13.25M▲ 0% | -138.32M▼ 944.2% | -297.2M▼ 114.9% | -355.93M▼ 19.8% | -269.48M▲ 24.3% | -283.25M▼ 5.1% | -266.76M▲ 5.8% | -244.17M▲ 8.5% | -241.99M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - |
Income Tax | 0 | -7.55M | -11.9M | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 5.46% | 4% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -13.25M▲ 0% | -130.78M▼ 887.2% | -285.31M▼ 118.2% | -355.93M▼ 24.8% | -269.48M▲ 24.3% | -283.25M▼ 5.1% | -266.76M▲ 5.8% | -244.17M▲ 8.5% | -241.99M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - |
Net Income Growth % | - | -887.23% | -118.16% | -24.75% | 24.29% | -5.11% | 5.82% | 8.47% | -15.96% |
Net Income (Continuing) | -13.25M | -130.78M | -285.31M | -355.93M | -269.48M | -283.25M | -266.76M | -244.17M | -241.99M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.07▲ 0% | -0.70▼ 890.1% | -1.63▼ 132.9% | -2.14▼ 31.3% | -1.43▲ 33.2% | -1.46▼ 2.1% | -1.16▲ 20.5% | -0.96▲ 17.2% | -0.87▲ 0% |
EPS Growth % | - | -890.1% | -132.86% | -31.29% | 33.18% | -2.1% | 20.55% | 17.24% | -4.55% |
EPS (Basic) | -0.07 | -0.70 | -1.63 | -2.14 | -1.43 | -1.46 | -1.16 | -0.96 | - |
Diluted Shares Outstanding | 187.34M | 187.34M | 187.51M | 166.43M | 188.34M | 194.54M | 230.89M | 253.23M | 276.86M |
Basic Shares Outstanding | 187.34M | 187.34M | 187.51M | 166.43M | 188.34M | 194.54M | 230.89M | 253.23M | 276.86M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
SANA Balance Sheet
Sana Biotechnology, Inc. (SANA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 32.6M | 144.26M | 384.47M | 558.1M | 444.44M | 213.51M | 160.81M | 148.68M | 111.69M |
Cash & Short-Term Investments | 30.63M | 138.98M | 378.26M | 551M | 423.96M | 205.19M | 152.5M | 138.38M | 101.14M |
Cash Only | 30.63M | 80.03M | 124.81M | 253.03M | 176.76M | 133.52M | 127.57M | 71.87M | 83.8M |
Short-Term Investments | 0 | 58.95M | 253.46M | 297.97M | 247.2M | 71.68M | 24.93M | 66.51M | 17.34M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 0 | 20.47M | 8.32M | 8.31M | 10.29M | 10.55M |
Total Non-Current Assets | 1.74M | 270.93M | 345.83M | 571.31M | 378.28M | 351.78M | 340.21M | 268.21M | 261.9M |
Property, Plant & Equipment | 585K | 68.81M | 109.94M | 161.78M | 159.4M | 145.59M | 135.27M | 65.22M | 61.52M |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 140.63M | 140.63M | 140.63M | 140.63M | 140.63M | 140.63M | 140.63M | 140.63M |
Intangible Assets | 0 | 59.2M | 59.2M | 59.2M | 59.2M | 59.2M | 59.2M | 59.2M | 59.2M |
Long-Term Investments | 816K | 0 | 33.73M | 195.88M | 10.05M | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 336K | 2.3M | 2.33M | 13.82M | 9.01M | 6.37M | 5.12M | 3.17M | 563K |
Total Assets | 34.33M▲ 0% | 415.19M▲ 1109.3% | 730.3M▲ 75.9% | 1.13B▲ 54.7% | 822.72M▼ 27.2% | 565.3M▼ 31.3% | 501.02M▼ 11.4% | 416.89M▼ 16.8% | 373.59M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | 1109.31% | 75.89% | 54.65% | -27.15% | -31.29% | -11.37% | -16.79% | -96.63% |
Total Current Liabilities | 1.78M | 19.32M | 31.45M | 99.23M | 111.5M | 64.49M | 45.43M | 78.73M | 86.27M |
Accounts Payable | 289K | 0 | 2.25M | 2.22M | 2.86M | 4.11M | 5.21M | 1.67M | 2.12M |
Days Payables Outstanding | 105.48K | - | 80.85 | - | - | - | - | 47.78 | 302.26 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14.94M | 14.88M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 685K | 8.09M | 14.02M | 74.63M | 76.59M | 23.46M | 300K | 62.12M | 69.26M |
Current Ratio | 18.26x | 7.47x | 12.22x | 5.62x | 3.99x | 3.31x | 3.54x | 1.89x | 1.29x |
Quick Ratio | 18.26x | 7.47x | 12.22x | 5.62x | 3.99x | 3.31x | 3.54x | 1.89x | 1.29x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 45.74M | 538.41M | 1.12B | 301.67M | 211.9M | 213.31M | 205.08M | 177.28M | 168.09M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 60.45M |
Capital Lease Obligations | 0 | 46.36M | 68.2M | 101.78M | 95.86M | 90.9M | 81.66M | 63.92M | 210.55M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 45.74M | 492.05M | 1.05B | 199.89M | 116.04M | 122.41M | 123.42M | 113.36M | 107.64M |
Total Liabilities | 47.52M | 557.73M | 1.15B | 400.9M | 323.4M | 277.79M | 250.52M | 256.01M | 254.35M |
Total Debt | 0 | 47.7M | 71.91M | 110.94M | 108.25M | 104.1M | 94.2M | 78.86M | 75.33M |
Net Debt | -30.63M | -32.33M | -52.9M | -142.09M | -68.51M | -29.42M | -33.37M | 6.99M | -8.47M |
Debt / Equity | - | - | - | 0.15x | 0.22x | 0.36x | 0.38x | 0.49x | 0.63x |
Debt / EBITDA | - | - | - | - | - | - | - | - | -0.33x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | 0.04x |
Interest Coverage | - | - | - | - | - | - | - | - | - |
Total Equity | -13.19M▲ 0% | -142.54M▼ 980.8% | -421.18M▼ 195.5% | 728.5M▲ 273.0% | 499.31M▼ 31.5% | 287.51M▼ 42.4% | 250.5M▼ 12.9% | 160.88M▼ 35.8% | 119.24M▲ 0% |
Equity Growth % | - | -980.85% | -195.48% | 272.97% | -31.46% | -42.42% | -12.87% | -35.78% | -175.88% |
Book Value per Share | -0.07 | -0.76 | -2.25 | 4.38 | 2.65 | 1.48 | 1.08 | 0.64 | 0.43 |
Total Shareholders' Equity | -13.19M | -142.54M | -421.18M | 728.5M | 499.31M | 287.51M | 250.5M | 160.88M | 119.24M |
Common Stock | 1K | 1K | 2K | 18K | 19K | 20K | 22K | 27K | 27K |
Retained Earnings | -13.25M | -144.13M | -429.43M | -785.36M | -1.05B | -1.34B | -1.6B | -1.85B | -1.9B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -45.72M | 26K | 30K | -1.37M | -4.33M | -60K | 14K | 28K | -2K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SANA Cash Flow Statement
Sana Biotechnology, Inc. (SANA) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -13.49M | -85.5M | -137.98M | -251.05M | -290.05M | -253.58M | -223.15M | -143.83M | -132.55M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | - | -533.6% | -61.37% | -81.95% | -15.53% | 12.57% | 12% | 35.55% | 140.63% |
Net Income | -13.25M | -130.78M | -285.31M | -355.93M | -269.48M | -283.25M | -266.76M | -244.17M | -241.99M |
Depreciation & Amortization | 1K | 1.83M | 5.92M | 11.07M | 15.63M | 24.56M | 17.39M | 12.75M | 11.5M |
Stock-Based Compensation | 118K | 1.5M | 5.83M | 22.36M | 38.34M | 35.53M | 37.68M | 25.46M | 12.97M |
Deferred Taxes | 0 | -7.55M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -228K | 38.97M | 129.42M | 61.64M | -82.08M | -49.03M | -10.28M | 72.24M | 91.96M |
Working Capital Changes | -308K | 10.53M | 6.16M | 9.8M | 7.54M | 18.61M | -1.19M | -10.11M | -6.99M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 289K | -421K | 1.98M | -266K | 1.06M | 1.03M | 1.38M | -3.54M | -92K |
Cash from Investing | -780K | -87.86M | -252.56M | -245.8M | 210.56M | 172.01M | 17.45M | -40.24M | -7.4M |
Capital Expenditures | -460K | -26.18M | -23.87M | -29.86M | -20.88M | -20.03M | 0 | -938K | -1.09M |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | -3.19M | 0 | 0 | -231.44K | -192.04K | 0 | 1.43M | 1.02M |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | -320K | 59K | 0 | -4.57M | 231.44K | 192.04K | 17.45M | 0 | 7.59M |
Cash from Financing | 45.72M | 223.73M | 435.69M | 631.75M | 4.91M | 31.65M | 199.75M | 128.73M | 127.62M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 7.74M | -347K | -353K |
Equity Issued (Net) | 45.72M | 223.74M | 435.54M | 631.75M | 4.91M | 31.65M | 181M | 129.08M | 127.42M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | -14K | 149K | 0 | 0 | 0 | 11.01M | 0 | 551K |
Net Change in Cash | 31.45M▲ 0% | 50.36M▲ 60.2% | 45.14M▼ 10.4% | 134.9M▲ 198.8% | -74.58M▼ 155.3% | -49.92M▲ 33.1% | -5.95M▲ 88.1% | -55.33M▼ 829.8% | -12.33M▲ 0% |
Free Cash Flow | -13.96M▲ 0% | -111.69M▼ 700.3% | -161.85M▼ 44.9% | -280.92M▼ 73.6% | -310.93M▼ 10.7% | -273.61M▲ 12.0% | -256.58M▲ 6.2% | -144.77M▲ 43.6% | -133.64M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - |
FCF Growth % | - | -700.34% | -44.92% | -73.56% | -10.68% | 12% | 6.22% | 43.58% | 40.31% |
FCF per Share | -0.07 | -0.60 | -0.86 | -1.69 | -1.65 | -1.41 | -1.11 | -0.57 | -0.48 |
FCF Conversion (FCF/Net Income) | 1.02x | 0.65x | 0.48x | 0.71x | 1.08x | 0.90x | 0.84x | 0.59x | 0.55x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SANA Key Ratios
Sana Biotechnology, Inc. (SANA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | -231.63% | -43.9% | -72% | -99.17% | -118.7% | -161.87% |
Return on Invested Capital (ROIC) | - | - | -476.58% | -40.19% | -63.83% | -86.08% | -74.4% | -119.35% |
Debt / Equity | - | - | 0.15x | 0.22x | 0.36x | 0.38x | 0.49x | 0.63x |
FCF Conversion | 0.65x | 0.48x | 0.71x | 1.08x | 0.90x | 0.84x | 0.59x | 0.55x |
Related:SANA Dividend History·SANA Revenue History·SANA Price History·SANA P/E History·SANA Financial Ratios·SANA Institutional Holders
SANA SEC Filings & Documents
Sana Biotechnology, Inc. (SANA) SEC filings — annual & quarterly reports (10-K, 10-Q)
SANA Frequently Asked Questions
Sana Biotechnology, Inc. (SANA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Sana Biotechnology, Inc. (SANA) grew revenue by 0.0% over the past year. Growth has been modest.
Sana Biotechnology, Inc. (SANA) reported a net loss of $242.0M for fiscal year 2025.
Dividend & Returns
Sana Biotechnology, Inc. (SANA) has a return on equity (ROE) of -118.7%. Negative ROE indicates the company is unprofitable.
Sana Biotechnology, Inc. (SANA) had negative free cash flow of $133.6M in fiscal year 2025, likely due to heavy capital investments.